Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54,444 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial.
Zhou Q, Yu Y, Xing L, Cheng Y, Wang Y, Pan Y, Fan Y, Shi J, Zhang G, Cui J, Zhou J, Song Y, Zhuang W, Ma Z, Hu Y, Li G, Dong X, Feng J, Lu S, Wu J, Li J, Zhang L, Wang D, Xu X, Yang TY, Yang N, Guo Y, Zhao J, Yao Y, Zhong D, Xia B, Yang CT, Zhu B, Sun P, Shim BY, Chen Y, Wang Z, Ahn MJ, Wang J, Wu YL. Zhou Q, et al. Among authors: zhou j. Med. 2024 Oct 3:S2666-6340(24)00344-1. doi: 10.1016/j.medj.2024.09.002. Online ahead of print. Med. 2024. PMID: 39389055
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, Wang D, Li Q, Qin S, Hu C, Zhang Y, Chen J, Cheng Y, Feng J, Zhang H, Song Y, Wu YL, Xu N, Zhou J, Luo R, Bai C, Jin Y, Liu W, Wei Z, Tan F, Wang Y, Ding L, Dai H, Jiao S, Wang J, Liang L, Zhang W, Sun Y. Shi Y, et al. Among authors: zhou j, zhou c. Lancet Oncol. 2013 Sep;14(10):953-61. doi: 10.1016/S1470-2045(13)70355-3. Epub 2013 Aug 13. Lancet Oncol. 2013. PMID: 23948351 Clinical Trial.
[Consensus on dignosis for ALK positive non-small cell lung cancer in China, the 2013 version].
Zhang XC, Lu S, Zhang L, Wang CL, Cheng Y, Li GD, Mok T, Huang C, Liu XQ, Wang J, Wang MZ, Zhang YP, Zhou JY, Zhou XY, Lin DM, Yang JJ, Li H, Chen HQ, Zhong WZ, Wu YL. Zhang XC, et al. Among authors: zhou jy, zhou xy. Zhonghua Bing Li Xue Za Zhi. 2013 Jun;42(6):402-6. doi: 10.3760/cma.j.issn.0529-5807.2013.06.012. Zhonghua Bing Li Xue Za Zhi. 2013. PMID: 24060077 Chinese. No abstract available.
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS. Soria JC, et al. Among authors: zhou jy. Lancet Oncol. 2015 Aug;16(8):990-8. doi: 10.1016/S1470-2045(15)00121-7. Epub 2015 Jul 6. Lancet Oncol. 2015. PMID: 26159065 Clinical Trial.
Current small cell lung cancer treatment in China.
Shi Y, Xing P, Fan Y, Zhang X, Hu C, Wang C, Liu X, Chen X, Zhou J, Wang M, Wu M, Han B, Fan M. Shi Y, et al. Among authors: zhou j. Thorac Cancer. 2015 May;6(3):233-8. doi: 10.1111/1759-7714.12218. Epub 2015 Jan 15. Thorac Cancer. 2015. PMID: 26273367 Free PMC article. Review.
The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study.
Hu X, Zhang L, Shi Y, Zhou C, Liu X, Wang D, Song Y, Li Q, Feng J, Qin S, Xv N, Zhou J, Zhang L, Hu C, Zhang S, Luo R, Wang J, Tan F, Wang Y, Ding L, Sun Y. Hu X, et al. Among authors: zhou j, zhou c. PLoS One. 2015 Nov 24;10(11):e0142500. doi: 10.1371/journal.pone.0142500. eCollection 2015. PLoS One. 2015. PMID: 26599904 Free PMC article. Clinical Trial.
[Guideline for diagnosis and treatment of ALK positive non-small cell lung cancer in China].
Zhang X, Lu S, Zhang L, Liao M, Wang C, Cheng Y, Li G, Tony M, Huang C, Liu X, Wang J, Wang M, Zhang Y, Zhou J, Zhou X, Zhou X, Lin D, Yang J, Song Y, Wang K, He Y, Li H, Zhong W, Wu Y. Zhang X, et al. Among authors: zhou x, zhou j. Zhonghua Bing Li Xue Za Zhi. 2015 Oct;44(10):696-703. Zhonghua Bing Li Xue Za Zhi. 2015. PMID: 26702525 Chinese. No abstract available.
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non‒Small-Cell Lung Cancer.
Lu S, Chang J, Liu X, Shi J, Lu Y, Li W, Yang JJ, Zhou J, Wang J, An T, Yang L, Liu Z, Zhou X, Chen M, Hua Y, Su W. Lu S, et al. Among authors: zhou x, zhou j. J Clin Oncol. 2018 Apr 20;36(12):1207-1217. doi: 10.1200/JCO.2017.76.7145. Epub 2018 Mar 12. J Clin Oncol. 2018. PMID: 29528793 Clinical Trial.
54,444 results
You have reached the last available page of results. Please see the User Guide for more information.